Analysts See $-0.17 EPS for Affimed N.V. (AFMD)

October 13, 2018 - By Marguerite Chambers

Analysts expect Affimed N.V. (NASDAQ:AFMD) to report $-0.17 EPS on November, 6.They anticipate $0.04 EPS change or 19.05 % from last quarter’s $-0.21 EPS. After having $-0.16 EPS previously, Affimed N.V.’s analysts see 6.25 % EPS growth. The stock increased 2.11% or $0.07 during the last trading session, reaching $3.38. About 563,085 shares traded. Affimed N.V. (NASDAQ:AFMD) has risen 126.19% since October 13, 2017 and is uptrending. It has outperformed by 110.57% the S&P500.

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 2 analysts covering Affimed (NASDAQ:AFMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Affimed had 3 analyst reports since August 9, 2018 according to SRatingsIntel. BMO Capital Markets maintained the shares of AFMD in report on Tuesday, August 28 with “Outperform” rating. As per Tuesday, August 28, the company rating was upgraded by Jefferies. The firm has “Outperform” rating given on Thursday, August 9 by BMO Capital Markets.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $210.88 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More news for Affimed N.V. (NASDAQ:AFMD) were recently published by:, which released: “Pre-Open Movers 10/09: (PYX) (PEIX) (PZZA) Higher; (TRVN) (AFMD) (BLKB) Lower (more…)” on October 09, 2018.‘s article titled: “Mid-Day Market Update: Blackbaud Drops On Lowered FY18 Outlook; Agile Therapeutics Shares Surge” and published on October 09, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.